Results demonstrated that zolbetuximab significantly inhibited tumor growth in both therapies, particularly when combined with chemotherapy, which increased the infiltration of CD8+ T cells and was more efficient in tumor growth inhibition when coupled with anti-mouse programmed cell death-1 (anti-mPD-1) therapy. Here, CD8A is linked to neoplasm.